Schnitzler syndrome, a rare autoinflammatory disease. Complete response to IL-1 blockade (original) (raw)

Abstract

The Schnitzler syndrome (SCS) is a rare, late-onset acquired autoinflammatory syndrome often underdiagnosed. The diagnosis is based on the Lipsker and recently on validated Strasbourg diagnostic criteria (chronic urticarial rash, monoclonal gammopathy, intermittent fever, arthritis, arthralgia, bone involvement, hepatomegaly, splenomegaly, lymphadenopathy, dermal infiltration of neutrophils and laboratory markers of inflammation). Conventional therapies including anti-histamines, anti-inflammatory drugs, corticosteroids and immunosuppressive drugs that are usually ineffective. Recently the gold standard therapy of SCS are considered IL-1 blocking agents as anakinra, canakinumab, rilonacept that led to a significant control of clinical symptoms, even if a relapse could appear at suspension of the treatment. We report a case of a 63-year-old man with a recent diagnosis of SCS - after 6 years of symptoms of disease - refractory to several conventional immunosuppressive therapies and tr...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (19)

  1. Schnitzler L. Lésions urticariennes chroniques permanentes (erythème pétaloide?) Cas Clinique. J Dermatol Angers 1972;46 B.
  2. Lipsker D, Veran Y, Grunenberg F, et al. The Schnitzler syndrome. Four new cases and review of litherature. Medicine 2001;80:37-44.
  3. Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: diagnosis, treat- ment, and follow up. Allergy 2013;68:562-8.
  4. Gusdorf L, Asli B, Barbarot S, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy 2017;72:177- 82.
  5. Gameiro A, Gouveia M, Pereira M, et al. Clinical characterization and long- term follow-up of Schnitzler syndrome. Clin Exp Dermatol 2016;41:461-7.
  6. Jain T, Offord Cp, Kyle R, et al. Schnitzler syndrome: an under-diag- nosed clinical entity. Haematologica 2013;98:1581-5.
  7. Gusdorf L, Lipsker D. Schnitzler syn- drome: a review. Curr Rheumatol Rep 2017;19:46-51.
  8. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010;s38:1-8.
  9. De Koning HD. Schnitzler's syndrome: lessons from 281 cases. Clin Transl Allergy 2014;4:41-56.
  10. Née A, Benoit H, Barbarot S, et al. Long term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome. A French multicentric study. Autoimmun Rev 2014;13:1035-41.
  11. De Koning HD, Schalkwijk J, Van Der Ven-Jongekrijg J, et al. Sustained effi- cacy of the monoclonal antiinterleukin- 1b antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis 2013;72:1634-38.
  12. Terpos E, Asli B, Christoulas D, et al. Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica 2012;97:1699-703.
  13. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syn- drome: an open-label study. Allergy 2012;67:943-50.
  14. Saurat JH, Schifferli J, Steiger G, et al L. Anti-interleukin-1 alpha autoantibod- ies in humans: characterization, isotype distribution, and receptor-binding inhi- bition-higher frequency in Schnitzler's syndrome (urticaria and macroglobu- linemia). J Allergy Clin Immunol 1991; 88:244-56.
  15. Migliorini P, Del Corso I, Tommasi C, Boraschi D. Free circulating inter- leukin-18 is increased in the Schnitzler syndrome: a new autoinflammatory dis- ease. Eur Cytokine Netw 2009;20:108.
  16. Vanderschueren S, van der Veen A. The Schnitzler syndrome: chronic urticaria in disguise: a single-centre report of 11 cases and a critical reappraisal of the lit- erature. Clin Exp Rheumatol 2017;35: 69-73.
  17. Gouveia AI, Micaelo M, Pierdomenico F, Freitas JP. Schnitzler syndrome: a dramatic response to anakinra. Dermatol Ther 2016;6:299-302.
  18. Kahlenberg JM. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade. Curr Opinion Rheumatol 2016;28:197-203.
  19. Krause K, Feist E, Fiene M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848- 50.